Abstract
Acute graft-vs.-host disease (GVHD) remains one of the most significant barriers to successful allogeneic stem cell transplantation, accounting for a substantial portion of early transplant-related morbidity and mortality. Acute GVHD results from the complex interaction of donor T cells and host tissues that involves recognition of major and minor histocompatibility antigens in an inflammatory milieu. The current view of the pathogeneisis of acute GVHD is that it involves three steps: (1) tissue damage from conditioning regimen, (2) donor T-cell activation and (3) an inflammatory effector phase [1]. Recent studies demonstrating the importance of chemokines and regulatory T cells in acute GVHD have added further complexity to this model [2]. Within this context, clinical strategies that mitigate host tissue damage, down-regulate activated effector donor T cells, and reduce inflammatory cytokines in the early post transplant period should be effective in treating or preventing this condition. Indeed, strategies based, at least in part, on this model have continued to aid in the development of newer agents with promise in acute GVHD. However, until recently, it is only the cellular attack on host tissues that has been specifically targeted by GVHD prophylactic mechanisms, either with the use of a variety of pharmacologic agents or graft manipulation techniques, whereas therapeutics for the treatment of established acute GVHD have invoked the role of the cytokine cascades that may perpetuate ongoing GVHD reactions. In this article, we will review the current standards for prevention and treatment of acute GVHD, and discuss novel drugs and therapeutics that hold promise for improved prevention and management of established acute GVHD.
Keywords: Acute GVHD, Novel Drugs, allogeneic stem cell transplantation, minor histocompatibility antigens, inflammatory milieu, pathogeneisis, inflammatory cytokines
Current Pharmaceutical Design
Title: Novel Drugs for the Prevention and Treatment of Acute GVHD
Volume: 14 Issue: 20
Author(s): Corey Cutler and Joseph H. Antin
Affiliation:
Keywords: Acute GVHD, Novel Drugs, allogeneic stem cell transplantation, minor histocompatibility antigens, inflammatory milieu, pathogeneisis, inflammatory cytokines
Abstract: Acute graft-vs.-host disease (GVHD) remains one of the most significant barriers to successful allogeneic stem cell transplantation, accounting for a substantial portion of early transplant-related morbidity and mortality. Acute GVHD results from the complex interaction of donor T cells and host tissues that involves recognition of major and minor histocompatibility antigens in an inflammatory milieu. The current view of the pathogeneisis of acute GVHD is that it involves three steps: (1) tissue damage from conditioning regimen, (2) donor T-cell activation and (3) an inflammatory effector phase [1]. Recent studies demonstrating the importance of chemokines and regulatory T cells in acute GVHD have added further complexity to this model [2]. Within this context, clinical strategies that mitigate host tissue damage, down-regulate activated effector donor T cells, and reduce inflammatory cytokines in the early post transplant period should be effective in treating or preventing this condition. Indeed, strategies based, at least in part, on this model have continued to aid in the development of newer agents with promise in acute GVHD. However, until recently, it is only the cellular attack on host tissues that has been specifically targeted by GVHD prophylactic mechanisms, either with the use of a variety of pharmacologic agents or graft manipulation techniques, whereas therapeutics for the treatment of established acute GVHD have invoked the role of the cytokine cascades that may perpetuate ongoing GVHD reactions. In this article, we will review the current standards for prevention and treatment of acute GVHD, and discuss novel drugs and therapeutics that hold promise for improved prevention and management of established acute GVHD.
Export Options
About this article
Cite this article as:
Cutler Corey and Antin H. Joseph, Novel Drugs for the Prevention and Treatment of Acute GVHD, Current Pharmaceutical Design 2008; 14 (20) . https://dx.doi.org/10.2174/138161208785061436
DOI https://dx.doi.org/10.2174/138161208785061436 |
Print ISSN 1381-6128 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-4286 |
Call for Papers in Thematic Issues
"Tuberculosis Prevention, Diagnosis and Drug Discovery"
The Nobel Prize-winning discoveries of Mycobacterium tuberculosis and streptomycin have enabled an appropriate diagnosis and an effective treatment of tuberculosis (TB). Since then, many newer diagnosis methods and drugs have been saving millions of lives. Despite advances in the past, TB is still a leading cause of infectious disease mortality ...read more
Current Pharmaceutical challenges in the treatment and diagnosis of neurological dysfunctions
Neurological dysfunctions (MND, ALS, MS, PD, AD, HD, ALS, Autism, OCD etc..) present significant challenges in both diagnosis and treatment, often necessitating innovative approaches and therapeutic interventions. This thematic issue aims to explore the current pharmaceutical landscape surrounding neurological disorders, shedding light on the challenges faced by researchers, clinicians, and ...read more
Emerging and re-emerging diseases
Faced with a possible endemic situation of COVID-19, the world has experienced two important phenomena, the emergence of new infectious diseases and/or the resurgence of previously eradicated infectious diseases. Furthermore, the geographic distribution of such diseases has also undergone changes. This context, in turn, may have a strong relationship with ...read more
Melanoma and Non-Melanoma Skin Cancer Treatment: Standard of Care and Recent Advances
In this thematic issue, we aim to provide a standard of care of the diagnosis and treatment of melanoma and non-melanoma skin cancer. The editor will invite authors from different countries who will write review articles of melanoma and non-melanoma skin cancers. The Diagnosis, Staging, Surgical Treatment, Non-Surgical Treatment all ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
The Antioxidant Effects of Radix Astragali (Astragalus membranaceus and Related Species) in Protecting Tissues from Injury and Disease
Current Drug Targets Effects of Dietary Mycotoxins on Gut Microbiome
Protein & Peptide Letters Fragment-Based Drug Design: Computational and Experimental State of the Art
Combinatorial Chemistry & High Throughput Screening Editorial [Hot topic: Acute Health Effects of Passive Smoking (Guest Editor: Andreas D. Flouris)]
Inflammation & Allergy - Drug Targets (Discontinued) Oral HPV Infection: Current Strategies for Prevention and Therapy
Current Pharmaceutical Design Rosmarinic Acid as Potential Anti-Inflammatory Agent
Reviews on Recent Clinical Trials AIDS-Related Kaposis Sarcoma: State of the Art and Therapeutic Strategies
Current HIV Research Peripheral Arterial Disease: The Magnitude of the Problem and its Socioeconomic Impact
Current Drug Targets - Cardiovascular & Hematological Disorders Chemokine Like Receptor-1 (CMKLR-1) Receptor: A Potential Therapeutic Target in Management of Chemerin Induced Type 2 Diabetes Mellitus and Cancer
Current Pharmaceutical Design Uncontrolled Hypertension and Oncology: Clinical Tips
Current Vascular Pharmacology Unraveling Major Proteins of <i>Mycobacterium tuberculosis</i> Envelope
Current Proteomics Otitis Media: Epidemiology and Management
Infectious Disorders - Drug Targets How Cancer Cells Resist Chemotherapy: Design and Development of Drugs Targeting Protein-Protein Interactions
Current Topics in Medicinal Chemistry Synthetic Peptide Mimics of the Bowman-Birk Inhibitor Protein
Current Medicinal Chemistry Molecular Aspects of Stromal-Parenchymal Interactions in Malignant Neoplasms
Current Molecular Medicine JAK2 as a Molecular Marker in Myeloproliferative Diseases
Cardiovascular & Hematological Agents in Medicinal Chemistry Management of Early Stage Chronic Myeloid Leukemia: State-of-the-art Approach and Future Perspectives
Current Cancer Drug Targets Loteprednol Etabonate Nanoparticles: Optimization via Box-Behnken Design Response Surface Methodology and Physicochemical Characterization
Current Drug Delivery Immune Modulation by Ionizing Radiation and its Implications for Cancer Immunotherapy
Current Pharmaceutical Design Estrogen Receptor Alpha: Impact of Ligands on Intracellular Shuttling and Turnover Rate in Breast Cancer Cells
Current Cancer Drug Targets